Seedat Y K
S Afr Med J. 1979 Dec 1;56(23):983-6.
Captopril (SQ 14,225), an angiotensin-converting enzyme inhibitor, was used in combination with propranolol, a beta-adrenergic blocking agent, in the treatment of mild and moderate hypertension. A significant decrease in blood presure was obtained (P less than 0.05). The maximum oral dose of captopril was 450 mg daily and the maximum oral dosage of propranolol was 360 mg daily. Side-effects were negligible and transitory. They consisted of skin rashes and pain in the calves (1 patient) and palpitations (1 patient) on captopril and skin rashes (1 patient) on propranolol. Captopril is a promising new hypotensive agent and is efficacious in combination with beta-adrenergic blocking agents.
卡托普利（SQ 14,225），一种血管紧张素转换酶抑制剂，与β-肾上腺素能阻滞剂普萘洛尔联合用于治疗轻、中度高血压。血压显著下降（P＜0.05）。卡托普利的最大口服剂量为每日450毫克，普萘洛尔的最大口服剂量为每日360毫克。副作用轻微且短暂。副作用包括卡托普利引起的皮疹、小腿疼痛（1例患者）和心悸（1例患者）以及普萘洛尔引起的皮疹（1例患者）。卡托普利是一种有前景的新型降压药，与β-肾上腺素能阻滞剂联合使用有效。
